IDRx

IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care through intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer drugs by using highly efficient and selective targeted therapies to block key tumor escape mechanisms and extend treatment response. IDRx’s lead program is IDRX-42, designed to inhibit critical genetic drivers and resistance mutations of KIT in GIST.